Results 41 to 50 of about 8,223,249 (171)
Louisiana Health Gaps Report: What's Driving Health Differences Across the State and How Can Those Gaps Be Closed? [PDF]
, 2015 Why is there so much difference in the health of residents in one county compared to other counties in the same state? In this report, the County Health Rankings & Roadmaps program explores how wide gaps are throughout Louisiana and what is driving those
Bridget Catlin +2 more
core
Pediatric Blood &Cancer, EarlyView.ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost +10 more
wiley +1 more source
Protecting America's Future: A State-by-State Look at SCHIP and Uninsured Kids [PDF]
, 2007 Presents findings from a comprehensive state-by-state analysis of children's access to health insurance and health care, and how that has changed since State Children's Health Insurance Program (SCHIP) was signed into law in ...
core
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender +17 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background L‐asparaginase is a critical component in treatment protocols for pediatric acute lymphoblastic leukemia. Acute pancreatitis reactions can necessitate delays and, in some cases, discontinuation of L‐asparaginase, which compromises outcomes.
Edward J. Raack +39 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods A multicenter retrospective review was performed
Hannah N. Rinehardt +76 more
wiley +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction Patients with ovarian cancer often present with massive ascites, leading to significant protein loss during surgical procedures. Although cell‐free concentrated ascites reinfusion therapy (CART) is used in palliative settings to mitigate protein loss, its application in intraoperative settings remains unexplored.
Yutaka Yoneoka +7 more
wiley +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Secondary hyperparathyroidism (SHPT) is a common complication in patients receiving maintenance dialysis, driven by calcium and phosphate metabolism disturbances. Calcimimetics are central to the management of SHPT by enhancing calcium‐sensing receptor sensitivity and reducing parathyroid hormone secretion.
Fumihiko Koiwa +3 more
wiley +1 more source